DOI: Published online: July 24, 2025 1 Institute of Medical Research, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea 2 Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea Correspondence to Seok-Woo Hong, PhD Institute of Medical Research, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, 29 Saemunan-ro, Jongno-gu, Seoul 03181, Korea Email: [email protected] Won-Young Lee, MD Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, 29 Saemunan-ro, Jongno-gu, Seoul 03181, Korea Email: [email protected] *Jinmi Lee and Eun-Jung Rhee contributed equally to this work as co-first authors
These findings suggest TGR as a key target for antischistosomal drug development
Start your intake Clinical Trial Data: Context and Individual Variation Tirzepatide's dual GLP-1 and GIP receptor agonism produced mean weight loss of 22.5% over 68 weeks in SURMOUNT-1 trials, compared to semaglutide's approximately 14-15% at comparable follow-up
PlexusDx supplies only these small-gauge needles with compounded semaglutide, ensuring maximum comfort with each dose
Some people may experience constant feelings of being full, dizziness, lethargy, diarrhea, gastrointestinal discomfort or nausea while increasing semaglutide dosages
Inhibition of glutamate-cysteine ligase (GCL), an important enzyme in GSH biosynthesis, is the most widely used method to inhibit GSH biosynthesis